Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Molecular signature of sleeping nociceptors offers new pain targets

4

Feb 2026

Molecular signature of sleeping nociceptors offers new pain targets

Researchers from the Centre for Addiction and Mental Health (CAMH) and the Institute of Neurophysiology at Uniklinik RWTH Aachen in Germany have deciphered the molecular signature of so-called sleeping nociceptors-a type of pain-sensing nerve cell that normally remains quiet and does not respond to touch or pressure, but can become overactive and drive chronic pain.

World Cancer Day marks broader access to NCCN patient resources

4

Feb 2026

World Cancer Day marks broader access to NCCN patient resources

The National Comprehensive Cancer Network (NCCN)-an alliance of leading cancer centers based in the United States-and the NCCN Foundation® is honoring World Cancer Day with an announcement about more frequent updates to its free educational resources intended to empower shared decision-making.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.